U.S. Computational Biology Market Summary

The U.S. computational biology market was valued at USD 2.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.1% from 2024 to 2030. The continuous discoveries and advancements in fields such as genomics, molecular biology, cellular and tissue engineering, bio-imaging, new drug discovery, and innovative drug delivery techniques are expected to open new avenues for enhancing diagnostic accuracy and expanding the range of therapeutic interventions available to healthcare professionals and researchers in the United States.

A significant portion of clinical development efforts related to life sciences technologies—particularly in the areas of oncology and infectious diseases—is concentrated in the U.S. The successful mapping of the human genome through the Human Genome Project has been a key milestone, catalyzing the development of personalized medicine. The pace of research, development, and commercialization of personalized medical services and products is significantly faster in the U.S. compared to other global markets. In addition, the incorporation of automated technologies is expected to further promote the adoption of life sciences tools by end users. For example, Smart Extraction technology developed by Analytik Jena facilitates the high-yield, high-quality extraction of high molecular weight DNA across diverse sample types. This form of automation enhances operational workflows, increases efficiency, and ensures improved DNA quality and yield.

Key Market Trends & Insights

• The software platforms segment held the largest market share of 39.2% in 2023 and is projected to witness the fastest growth rate from 2024 to 2030. This segment includes a wide variety of tools and technologies such as data analysis platforms, bioinformatics applications, modeling software, and simulation platforms, which are increasingly being utilized to accelerate and improve the accuracy of biological research and applications. The expanding complexity of biological data continues to drive demand for these platforms.
• In 2023, clinical trials accounted for the highest share in terms of application, representing 26.9% of the total market. This dominant position can be attributed to the rising demand for innovations in drug discovery and development, the growing importance of personalized medicine, and the need for accurate target identification and validation. Furthermore, as access to patient data—such as genomics and electronic health records—improves, computational biology is playing a critical role in interpreting large datasets and enabling informed decision-making during clinical trials.
• The industrial segment dominated the market with a substantial share of 62.6% in 2023. This is largely due to increasing progress in analyzing and visualizing biological structures in commercial settings. As biotechnology companies strive to gain deeper insights into metabolic processes and interactions, the integration of advanced technologies like artificial intelligence and machine learning is becoming increasingly prevalent. These technologies are enabling organizations to make faster and more accurate predictions and accelerate the research-to-market timeline.
• Meanwhile, the academics and research segment is expected to exhibit the fastest CAGR during the forecast period. This projected growth is driven by the increasing reliance on computational software to advance genome analysis, combined with growing research and development efforts being undertaken by academic institutions and scientific research organizations. The rising trend of collaboration between universities and biotech firms is also expected to accelerate the adoption of computational biology tools in research environments.

Order a free sample PDF of the U.S. Computational Biology Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2023 Market Size: USD 2.54 billion
• 2030 Projected Market Size: USD 6.01 billion
• CAGR (2024 - 2030): 13.1%

Key Companies & Market Share Insights

Key U.S. computational biology companies include Thermo Fisher Scientific, Inc.; DNAnexus, Inc.; and Illumina, Inc. among others. Leading companies are focusing on extensive R&D activities for the development of technologically advanced and cost-efficient products. Several business strategies, including new product launches and mergers & acquisitions are being undertaken by the companies to expand their market presence.

Key Players

• DNAnexus, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Schrodinger, Inc.
• Compugen
• Aganitha AI Inc.
• Genedata AG
• QIAGEN
• Simulations Plus, Inc.
• Fios Genomics

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. computational biology market is poised for robust growth due to the nation’s leadership in genomics, personalized medicine, and clinical research. Increasing adoption of software platforms, advancements in AI-driven data analysis, and automation technologies are expected to accelerate discovery and development processes. High involvement in clinical trials, industrial innovation, and academic research further bolsters the market's trajectory. With continuous investments and supportive infrastructure, the U.S. is likely to remain at the forefront of computational biology. The convergence of biotechnology, machine learning, and automation is paving the way for a more efficient, accurate, and scalable future in biological sciences.